EE231 The Real-World Cost-Effectiveness of Faricimab Versus Existing and Future Biosimilars in Patients with Neovascular Age-Related Macular Degeneration in the UK
Abstract
Authors
Christian Bührer Oliver Cox Marloes Bagijn Katharina Wodenitscharow Max Bourgognon